Loading...

Arch Biopartners

TSXV:ARCH
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ARCH
TSXV
$52M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
ARCH Share Price and Events
7 Day Returns
1.7%
TSXV:ARCH
-0.7%
North America Life Sciences
-0%
CA Market
1 Year Returns
-23.9%
TSXV:ARCH
19.1%
North America Life Sciences
-2.2%
CA Market
ARCH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arch Biopartners (ARCH) 1.7% -3.3% -7.8% -23.9% 131.4% -
North America Life Sciences -0.7% -4.2% 5% 19.1% 80.6% 108.7%
CA Market -0% -0.4% -2.6% -2.2% 8.1% -0.1%
1 Year Return vs Industry and Market
  • ARCH underperformed the Life Sciences industry which returned 19.1% over the past year.
  • ARCH underperformed the Market in Canada which returned -2.2% over the past year.
Price Volatility
ARCH
Industry
5yr Volatility vs Market

Value

 Is Arch Biopartners undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Arch Biopartners is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arch Biopartners has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arch Biopartners. This is due to cash flow or dividend data being unavailable. The share price is CA$1.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arch Biopartners's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arch Biopartners's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:ARCH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.06
OTCPK:ACHF.F Share Price ** OTCPK (2019-07-19) in USD $0.89
OTCPK:ACHF.F Share Price converted to CAD reporting currency Exchange rate (USD/ CAD) 1.308 CA$1.16
North America Life Sciences Industry PE Ratio Median Figure of 22 Publicly-Listed Life Sciences Companies 39.39x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 15.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arch Biopartners.

TSXV:ARCH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:ACHF.F Share Price ÷ EPS (both in CAD)

= 1.16 ÷ -0.06

-18.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arch Biopartners is loss making, we can't compare its value to the North America Life Sciences industry average.
  • Arch Biopartners is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Arch Biopartners's expected growth come at a high price?
Raw Data
TSXV:ARCH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -18.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Life Sciences Industry PEG Ratio Median Figure of 20 Publicly-Listed Life Sciences Companies 2.7x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 1.23x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Arch Biopartners, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Arch Biopartners's assets?
Raw Data
TSXV:ARCH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$-0.04
OTCPK:ACHF.F Share Price * OTCPK (2019-07-19) in USD $0.89
OTCPK:ACHF.F Share Price converted to CAD reporting currency Exchange rate (USD/ CAD) 1.308 CA$1.16
North America Life Sciences Industry PB Ratio Median Figure of 42 Publicly-Listed Life Sciences Companies 4.69x
Canada Market PB Ratio Median Figure of 2,445 Publicly-Listed Companies 1.46x
TSXV:ARCH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:ACHF.F Share Price ÷ Book Value per Share (both in CAD)

= 1.16 ÷ -0.04

-30.07x

* Primary Listing of Arch Biopartners.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arch Biopartners has negative assets, we can't compare the value of its assets to the North America Life Sciences industry average.

Next steps:

  1. Take a look at our analysis of ARCH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Arch Biopartners's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Life Sciences industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Arch Biopartners's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Arch Biopartners has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arch Biopartners expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arch Biopartners has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.2%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arch Biopartners expected to grow at an attractive rate?
  • Unable to compare Arch Biopartners's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Arch Biopartners's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Arch Biopartners's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:ARCH Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.2%
North America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:ARCH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:ARCH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 -2 -4
2018-12-31 -2 -4
2018-09-30 -2 -3
2018-06-30 -2 -3
2018-03-31 -1 -2
2017-12-31 -1 -2
2017-09-30 -1 -2
2017-06-30 -1 -2
2017-03-31 -1 -1
2016-12-31 -1 -1
2016-09-30 -1 -1
2016-06-30 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Arch Biopartners is high growth as no earnings estimate data is available.
  • Unable to determine if Arch Biopartners is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:ARCH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Arch Biopartners Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:ARCH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.06
2018-12-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.04
2017-12-31 -0.04
2017-09-30 -0.03
2017-06-30 -0.04
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arch Biopartners will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ARCH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Arch Biopartners's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Arch Biopartners's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Arch Biopartners's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arch Biopartners has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arch Biopartners performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arch Biopartners's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arch Biopartners does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Arch Biopartners's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Arch Biopartners's 1-year growth to the North America Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Arch Biopartners's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arch Biopartners Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:ARCH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -3.60 1.55
2018-12-31 -3.67 1.46
2018-09-30 -3.20 1.43
2018-06-30 -2.63 1.37
2018-03-31 -2.44 1.22
2017-12-31 -2.01 1.26
2017-09-30 -1.90 1.25
2017-06-30 -2.04 1.45
2017-03-31 -0.93 0.43
2016-12-31 -1.10 0.53
2016-09-30 -1.02 0.56
2016-06-30 0.04 -0.81 0.42
2016-03-31 0.00 -0.79 0.41
2015-12-31 0.00 -0.64 0.48
2015-09-30 0.04 -0.84 0.43
2015-06-30 0.03 -0.85 0.43
2015-03-31 0.08 -0.81 0.41
2014-12-31 0.09 -0.70 0.19
2014-09-30 0.05 -0.40 0.16
2014-06-30 0.06 -0.30 0.14 -0.01
2014-03-31 0.05 -0.19 0.12 -0.01
2013-12-31 0.04 -0.21 0.11 0.00
2013-09-30 0.04 -0.19 0.11
2013-06-30 -0.22 0.07 0.05
2013-03-31 -0.30 0.09 0.06
2012-12-31 -0.27 0.06 0.08
2012-09-30 -0.33 0.08 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Arch Biopartners has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Arch Biopartners has efficiently used its assets last year compared to the North America Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Arch Biopartners improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Arch Biopartners's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arch Biopartners has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arch Biopartners's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arch Biopartners's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arch Biopartners's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Arch Biopartners's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Arch Biopartners's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Arch Biopartners has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arch Biopartners Company Filings, last reported 3 months ago.

TSXV:ARCH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -2.27 1.94 0.07
2018-12-31 -1.83 1.45 0.25
2018-09-30 -1.05 1.48 0.54
2018-06-30 -0.27 1.46 1.31
2018-03-31 -0.25 1.45 1.32
2017-12-31 -0.91 0.85 0.17
2017-09-30 -0.56 0.35 0.04
2017-06-30 -0.53 0.32 0.02
2017-03-31 -0.25 0.33 0.28
2016-12-31 -0.49 0.33 0.06
2016-09-30 -0.28 0.33 0.20
2016-06-30 -0.05 0.33 0.42
2016-03-31 -0.19 0.34 0.28
2015-12-31 0.00 0.33 0.44
2015-09-30 0.14 0.33 0.62
2015-06-30 0.32 0.32 0.71
2015-03-31 0.49 0.32 0.87
2014-12-31 -0.16 0.33 0.25
2014-09-30 -0.01 0.35 0.37
2014-06-30 -0.28 0.37 0.18
2014-03-31 -0.15 0.38 0.27
2013-12-31 -0.48 0.42 0.00
2013-09-30 -0.43 0.40 0.03
2013-06-30 -0.47 0.39 0.00
2013-03-31 -0.45 0.38 0.01
2012-12-31 -0.39 0.37 0.02
2012-09-30 -0.36 0.37 0.07
  • Arch Biopartners has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Arch Biopartners's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Arch Biopartners has less than a year of cash runway based on current free cash flow.
  • Arch Biopartners has less than a year of cash runway if free cash flow continues to grow at historical rates of 51% each year.
X
Financial health checks
We assess Arch Biopartners's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arch Biopartners has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arch Biopartners's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arch Biopartners dividends.
If you bought CA$2,000 of Arch Biopartners shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arch Biopartners's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arch Biopartners's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:ARCH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 337 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arch Biopartners has not reported any payouts.
  • Unable to verify if Arch Biopartners's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arch Biopartners's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arch Biopartners has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arch Biopartners's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arch Biopartners afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arch Biopartners has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arch Biopartners's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Muruve
COMPENSATION CA$100,000
AGE 48
TENURE AS CEO 9.9 years
CEO Bio

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and serves as its President May 12, 2010. Mr. Muruve served as Acting Chief Financial Officer of Foccini International Inc. (Arch Biopartners Inc) until August 25, 2009. Mr. Muruve was employed at the Bank of Montreal in the Investment Banking Group for 12 years. He served as Vice President at BMO Nesbitt Burns. He served as Director of Foccini International Inc. since August 2005. He has been a Director of Arch Biopartners Inc., since August 2005. Mr. Muruve has a Master of Business Administration degree (MBA) from the University of British Columbia and a Bachelor of Commerce from McGill University.

CEO Compensation
  • Richard's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Richard's remuneration is about average for companies of similar size in Canada.
Management Team

Richard Muruve

TITLE
Co-Founder
COMPENSATION
CA$100K
AGE
48
TENURE
9.9 yrs

Dan Muruve

TITLE
Co-Founder

Andrew Bishop

TITLE
Acting CFO & Director
AGE
53

Justin MacDonald

TITLE
Co-Founder & Principal Scientist

Paul Beck

TITLE
Co-Founder & Principal Scientist
Board of Directors Tenure

Average tenure and age of the Arch Biopartners board of directors in years:

9.2
Average Tenure
58
Average Age
  • The tenure for the Arch Biopartners board of directors is about average.
Board of Directors

Richard Muruve

TITLE
Co-Founder
COMPENSATION
CA$100K
AGE
48
TENURE
13.9 yrs

Dan Muruve

TITLE
Co-Founder

Andrew Bishop

TITLE
Acting CFO & Director
AGE
53
TENURE
9.3 yrs

Conor Gunne

TITLE
Director
AGE
67
TENURE
9.2 yrs

Robert Hodges

TITLE
Member of Scientific Advisory Board

Richard Rossman

TITLE
Director
AGE
74
TENURE
9.2 yrs

Hindrik Mulder

TITLE
Member of Scientific Advisory Board

Claude Allary

TITLE
Director
TENURE
5.3 yrs

Adrian Haigh

TITLE
Director
AGE
60
TENURE
4.9 yrs

Patrick Vink

TITLE
Director
AGE
56
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
07. Dec 18 Sell John Heersink Individual 12. Sep 17 07. Aug 18 -1,545,000 CA$1.65 CA$-473,007
07. Dec 18 Buy John Heersink Individual 28. Feb 17 07. Aug 18 6,220,000 CA$1.64 CA$549,175
X
Management checks
We assess Arch Biopartners's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arch Biopartners has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.

Details
Name: Arch Biopartners Inc.
ARCH
Exchange: TSXV
Founded:
$68,331,902
58,712,302
Website: http://www.archbiopartners.com
Address: Arch Biopartners Inc.
545 King Street West,
Toronto,
Ontario, M5V 1M1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK ACHF.F Common Shares Pink Sheets LLC US USD 09. May 2010
TSXV ARCH Common Shares TSX Venture Exchange CA CAD 09. May 2010
Number of employees
Current staff
Staff numbers
0
Arch Biopartners employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:57
End of day share price update: 2019/07/19 00:00
Last earnings filing: 2019/05/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.